Sign In
Buy ACHV
$4.92
-0.110 (-2.19%)
At Close: Jun 03, 2026
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
08:00am, Tuesday, 09'th Jul 2024
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comme
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
01:46pm, Monday, 01'st Jul 2024
Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA t
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commer
Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript
07:58pm, Thursday, 09'th May 2024
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy J
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
04:01pm, Thursday, 09'th May 2024
Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
11:16am, Monday, 06'th May 2024
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
08:00am, Thursday, 25'th Apr 2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comm
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
06:30am, Thursday, 04'th Apr 2024
Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to exi
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
09:03pm, Thursday, 28'th Mar 2024
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
04:01pm, Thursday, 28'th Mar 2024
Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
08:00am, Wednesday, 06'th Mar 2024
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comm
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
08:01am, Thursday, 29'th Feb 2024
Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025 Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
08:00am, Thursday, 29'th Feb 2024
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants
Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?
09:10am, Tuesday, 12'th Dec 2023
Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administr
Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment
08:53am, Tuesday, 12'th Dec 2023
Achieve Life Sciences Inc. shares ACHV, -1.09% dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company's smoking cessation treatment cytisinicline. In a recent meet
